Form 8-K Intra-Cellular Therapies For: May 07
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/10/2026
- S&P 500, Dow futures attempt recovery ahead of inflation report
- Oracle raises full year profit guidance, stock rises after hours
- Oil surges 6%, Brent and US crude both surpass $100 on more tanker attacks
- Analysts split on Apple after foldable iPhone Duo debut
- JPMorgan upgrades Meta on AI models and agents, sees 'meaningful headroom'
- S&P 500 ends down as oil tops $100 per barrel
- White House copper tariff plan stalls amid affordability concerns, sources say
- Trump promises $5,000 payout to U.S. adults if Republicans win election
- Crude Inventory 0.4M Barrels Last Week - EIA
- Meta stock jumps 5% premarket: Analysts bullish on new Muse AI agent
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Intra-Cellular Therapies (ITCI) PT Lowered to $96 at RBC Capital
May 7, 2024 12:44 PM EDTRBC Capital analyst Brian Abrahams lowered the price target on Intra-Cellular Therapies (NASDAQ: ITCI) to $96.00 (from $100.00) while maintaining a Outperform rating.
The analyst comments "This morning ITCI reported 1Q24 earnings and we had a chance to catch up with mgmt to... More
JPMorgan on Intra-Cellular Therapies (ITCI): 'We continue to like ITCI stock'
May 7, 2024 12:32 PM EDTJPMorgan analyst Jessica Fye reiterated an Overweight rating and $75.00 price target on Intra-Cellular Therapies (NASDAQ: ITCI)
The analyst comments "We continue to like ITCI stock on the back of solid 1Q results and with shares having come off of their post-data highs. ITCI reported 1Q24 revenue of $145mm,... More
Jefferies Positive on Intra-Cellular Therapies (ITCI): 'We like the setup ahead of the second MDD readout in late-Q2'
May 7, 2024 8:00 AM EDTJefferies analyst Andrew Tsai reiterated a Buy rating and $105.00 price target on Intra-Cellular Therapies (NASDAQ: ITCI).
The analyst comments "ITCI previously preannounced a Q1 beat (Caplyta sales were $145M vs cons $141M), and mgmt just reiterated its 2024 guidance of $645-675M. Quarterly... More
